Mark James Litton net worth and biography

Mark Litton Biography and Net Worth

CEO of Athira Pharma

Mark is President and CEO of LeonaBio, a position he has held since October 2021. Previously, he served as LeonaBio’s COO since July 2019. Prior to joining LeonaBio, Mark served as the President and COO of Alpine Immune Sciences, Inc. Prior to that he spent more than 14 years at Alder Biopharmaceutical Inc., a publicly traded biopharmaceutical company, which was acquired by Lundbeck A/S. As co-founder and CBO, Mark helped build the business and oversaw finance, investor relations, deal making, business development, alliance management, human resources, and overall corporate strategy. While at Alder, Mark was directly responsible for raising over ~$1B in equity capital and led negotiations for numerous corporate alliances between biotech and pharmaceutical companies.

Mark has a PhD in immunology from Stockholm University, an MBA from Santa Clara University and a BA in Biochemistry and Molecular Biology from UC Santa Cruz.

What is Mark James Litton's net worth?: The estimated net worth of Mark James Litton is at least $339.74 thousand as of March 4th, 2026. Litton owns 57,926 shares of Athira Pharma stock worth more than $339,736 as of September 23rd. This net worth approximation does not reflect any other investments that Litton may own. Learn More about Mark James Litton's net worth.
How do I contact Mark James Litton?: The corporate mailing address for Litton and other Athira Pharma executives is 18706 North Creek Parkway, Suite 104, Bothell, WA, 98011. Athira Pharma can also be reached via phone at 425-620-8501 and via email at [email protected]. Learn More on Mark James Litton's contact information.
Has Mark James Litton been buying or selling shares of Athira Pharma?: Mark James Litton has not been actively trading shares of Athira Pharma during the last quarter. Most recently, Mark James Litton sold 5,156 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $5.37, for a transaction totalling $27,687.72. Following the completion of the sale, the chief executive officer now directly owns 57,926 shares of the company's stock, valued at $311,062.62. Learn More on Mark James Litton's trading history.
Who are Athira Pharma's active insiders?: Athira Pharma's insider roster includes Mark Litton (CEO), and Mark Worthington (General Counsel). Learn More on Athira Pharma's active insiders.
Are insiders buying or selling shares of Athira Pharma?: In the last twelve months, insiders at the sold shares 8 times. They sold a total of 14,513 shares worth more than $86,093.34. The most recent insider tranaction occured on March, 4th when insider Martin Javier San sold 1,720 shares worth more than $9,236.40. Insiders at Athira Pharma own 25.7% of the company. Learn More about insider trades at Athira Pharma.
Information on this page was last updated on 3/4/2026.

Mark James Litton Insider Trading History at Athira Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2026	Sell	5,156	$5.37	$27,687.72	57,926
1/2/2026	Sell	2,586	$6.88	$17,791.68	40,828
7/1/2025	Sell	2,512	$2.90	$7,284.80	32,580
1/2/2025	Sell	2,510	$5.60	$14,056.00	24,259
9/5/2024	Sell	503	$5.70	$2,867.10	15,936
1/5/2024	Sell	482	$29.10	$14,026.20	14,439
6/23/2022	Sell	796	$26.90	$21,412.40	12,855

Mark James Litton Buying and Selling Activity at Athira Pharma

Athira Pharma Company Overview

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Today's Range

Now: $5.90

$5.69

$6.35

50 Day Range

MA: $7.50

$6.05

$8.53

2 Week Range

Now: $5.90

$3.60

$14.21

Volume

20,068 shs

Average Volume

52,077 shs

Market Capitalization

$55.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.05